C.-H. Köhne - Concepedia

Author

C.-H. Köhne

Also Known As

A. Tannapfel, C -H Köhne, C H Köhne, C Köhne, C. H. Köhne, C. Kohne, C. Köhne, C.-H. Köhne, C.H. Köhne, Claus -Henning Köhne

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Klinikum Oldenburg Merck (Germany)Medizinische Hochschule Hannover Hôpital Ambroise-Paré Royal Marsden NHS Foundation Trust

About

C.-H. Köhne is an author at Klinikum Oldenburg specializing in colorectal cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.8K
2	Pathology	6	6	1.4K
3	Health Sciences	3	3	410
4	Hepatology	1	1	93
5	Immunology	1	1	93

C.-H. Köhne

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients C.-H. Köhne, David Cunningham, Francesco Di Costanzo, Annals of Oncology Clinical DeterminantsSurgical OncologyMultivariate AnalysisMedicineColorectal Cancer	2002	456
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial Eric Van Cutsem, Marek P. Nowacki, István Láng, Journal of Clinical Oncology PathologyPharmacotherapyCrystal TrialGastrointestinal OncologyClinical Trials	2007	314
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Gunnar Folprecht, David Cunningham, Paul J. Ross, Annals of Oncology 5-Fluorouracil-based ChemotherapyElderly PatientsGastrointestinal OncologyMedicinePharmacology	2004	256
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer Carsten Bokemeyer, C.-H. Köhne, Fortunato Ciardiello, European Journal of Cancer Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2015	241
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Gunnar Folprecht, Manfred P. Lutz, Patrick Schöffski, Annals of Oncology OncologyMedicineColorectal CancerPathologyIrinotecan/5-fluorouracil/folinic Acid	2005	233
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial Emmanouil Fokas, Rainer Fietkau, Arndt Hartmann, Annals of Oncology	2018	109
Relevance of Ki-67 antigen expression and K- ras mutation in colorectal liver metastases Henrik Petrowsky, Isrid Sturm, O. Graubitz, European Journal of Surgical Oncology K- Ras MutationHepatologyKi-67 Antigen ExpressionColorectal Liver MetastasesMedicine	2001	93
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification C.-H. Köhne, Daniel J. Sargent, Bengt Glimelius Annals of Oncology Surgical OncologyMedicinePrognosisColorectal CancerOutcomes Research	2007	84
Anatomical Variations in the Internal Jugular Veins of Cancer Patients Affecting Central Venous Access T. Benter, Ulf Teichgräber, L Klühs, Ultraschall in der Medizin - European Journal of Ultrasound	2001	45
6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status Eric Van Cutsem, P. Rougier, C.-H. Köhne, European Journal of Cancer Supplements MedicineColorectal CancerPathologyMetastatic Colorectal CancerOpus Studies	2009	42

Page 1